Glycolytic activity and in vitro effect of the pyruvate kinase activator <scp>AG</scp>‐946 in red blood cells from low‐risk myelodysplastic syndromes patients: A proof‐of‐concept study-Reference-Cited by-同舟云学术

Glycolytic activity and in vitro effect of the pyruvate kinase activator AG‐946 in red blood cells from low‐risk myelodysplastic syndromes patients: A proof‐of‐concept study

Published:2024-04-02 Issue:6 Volume:99 Page:1201-1204
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Fattizzo Bruno¹²^ORCID,Vercellati Cristina¹,Marcello Anna¹,Patel Parija³,Wind‐Rotolo Megan³,Pettine Loredana¹^ORCID,Bonanomi Marcella⁴⁵,Gaglio Daniela⁴⁵,Bortolotti Marta¹²^ORCID,Leoni Claudia¹²,Fermo Elisa¹,Bianchi Paola¹^ORCID,Zaninoni Anna¹^ORCID,Passamonti Francesco¹²,Barcellini Wilma¹^ORCID

Affiliation:

1. SC Ematologia, SS Fisiopatologia delle Anemie Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico Milan Italy

2. Department of Oncology and Hemato‐Oncology University of Milan Milan Italy

3. Agios Pharmaceuticals, Inc. Cambridge Massachusetts USA

4. Institute of Molecular Bioimaging and Physiology of the Italian National Research Council (IBFM‐CNR) Segrate (MI) Italy

5. ISBE Elixir European Infrastructure for Systems Biology Milan Italy

Funder

Agios Pharmaceuticals

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.27300

Reference6 articles.

1. Myelodysplastic Syndromes and Metabolism

2. Erythrocyte enzyme activities in myelodysplastic syndromes: Elevated pyruvate kinase activity

3. Red cell enzymes in myelodysplastic syndromes: A review

4. Pharmacodynamic Effects of AG-946, a Highly Potent Next-Generation Activator of Pyruvate Kinase, in Ex Vivo Treatment of Red Blood Cells from Sickle Cell Disease Patients

5. A Study of AG‐946 in Participants With Anemia Due to Lower‐Risk Myelodysplastic Syndromes (LR‐MDS). NCT05490446. Last accessed on 8 August 2023.